With the increasing demand for noninvasive approaches in monitoring head and neck cancer, circulating nucleic acids have been shown to be a promising tool. We focused on the global transcriptome of serum samples of head and neck squamous cell carcinoma (HNSCC) patients in comparison with healthy individuals. We compared gene expression patterns of 36 samples. Twenty-four participants including 16 HNSCC patients (from 12 patients we obtained blood samples 1 year posttreatment) and 8 control subjects were recruited. The Illumina HumanWG-6 v3 Expression BeadChip was used to profile and identify the differences in serum mRNA transcriptomes. We found 159 genes to be significantly changed (Storey's value < 0.05) between normal and cancer serum specimens regardless of factors including p53 and B-cell lymphoma family members (Bcl-2, Bcl-XL). In contrast, there was no difference in gene expression between samples obtained before and after surgery in cancer patients. We suggest that microarray analysis of serum cRNA in patients with HNSCC should be suitable for refinement of early stage diagnosis of disease that can be important for development of new personalized strategies in diagnosis and treatment of tumours but is not suitable for monitoring further development of disease.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is the fifth most common cancer worldwide. The overall incidence is half a million cases per year. HNSCC accounts for about 10% of the total cancer burden in men [1] . Its biological behaviour is typified by aggressive locoregional invasiveness, local recurrence, and tumour multiplicity. Despite considerable advances in surgical and oncological treatment over the past two decades, overall disease outcome has only slightly improved. The main reason for this is late diagnosis, with almost two-thirds of cases being diagnosed in the late stage of disease. The presence of lymph node metastasis is associated with a 50% decrease in 5-year survival and is the single most important prognostic factor identified to date [2] [3] [4] [5] . For better prognosis of patients and reduction of posttherapeutic morbidity, including significant discomfort, it is crucial to recognise the cancer at an early stage. Therefore, many scientists have dedicated much effort to identification of potential biomarkers involved in the process of carcinogenesis and investigation of the molecular characteristics of HNSCC.
The field of cancer research has continued to evolve rapidly, and, in recent years, there have been advances in our knowledge of the molecular biology and epigenetics 2 BioMed Research International of HNSCC as well as in the techniques available to study this disease. Development of high-throughput expressionarray-based techniques has led to the detection of novel tumour suppressor genes (TSGs) and protooncogenes, as well as a description of epigenetic modifications involved in tumourigenesis. Finally, the field of bioinformatics is now intimately involved in deciphering the data generated by these techniques. Many studies have yielded promising results in this field by analysing tumour tissue samples in comparison to normal mucosa [6] [7] [8] [9] [10] [11] . However, assays based on processing of tumour tissue samples do not resolve the problem of early diagnosis, and invasive tumour biopsy places great demands on the patient and is limited in size.
With the increasing demand for noninvasive approaches in the monitoring of cancer, circulating nucleic acids (CNAs) have been shown to be a promising tool. In the case of neoplasia, circulating RNA has been found to be a more sensitive marker than tumour-derived circulating DNA. The first study associating circulating RNA in the serum as a potential tumour marker was reported by Wieczorek et al. more than 20 years ago. That study reported an association between the presence of the RNA-proteolipid complex and the tumour response to therapy [12] . During the past 10 years, there has been a great leap forward in detecting and testing isolated cell-free RNA for different tumour-related transcripts [13, 14] , telomerase components [15] , or viral RNA transcripts. Tumour-associated RNA was detectable in the serum or plasma of patients with breast, liver, or lung cancer [16] , colorectal cancer [17] , follicular lymphoma [18] , prostate cancer [19] , malignant melanoma [20] , hepatocellular carcinoma, oesophageal carcinoma, and others [21, 22] . Unfortunately, almost no data are available on cRNA in patients with HNSCC. The detection and identification of cRNA can be carried out by using microarray technologies or reverse transcription quantitative real-time PCR [23] .
Detection of cell-free RNA in plasma and serum could potentially serve as a "liquid biopsy, " which would avoid the need for tumour tissue biopsies. This approach is especially favourable for its possibility of taking repeated blood samples during cancer development and progression, as well as during the monitoring of cancer treatment. Indeed the role of CNAs as blood biomarkers was recently highlighted [24] .
Materials and Methods
Twenty-four participants including 16 HNSCC patients (from 12 patients we obtained blood samples 1 year after treatment) and eight control subjects were recruited. The Illumina HumanWG-6 v3 Expression BeadChip was used to profile and identify the differences in serum mRNA transcriptomes between cancer patients and healthy controls as well as the differences in serum mRNA transcriptomes between serum from the same donor obtained before surgery and 1 year after treatment. Labeling. After purification, theamplified single-stranded cDNA was labeled with biotin according to the NuGEN Illumina Protocol.
Blood Specimens and Collection
Hybridization. Illumina HumanWG-6 v3 Expression BeadChip (Illumina, San Diego, CA, USA) was used for the microarray analysis following the standard protocol. Biotinlabeled cDNA (1.5 g) was hybridized, washed, and scanned according to the manufacturer's instructions, with the exception that the hybridization temperature was reduced to 48 ∘ C to accommodate the altered hybridization kinetics of cDNA/DNA pairs relative to cRNA/DNA pairs. All subsequent analyses were done on biological replicates.
Data Analysis.
The raw data (TIFF image files) were analysed using the BeadArray package [25] of the bioconductor within the R environment (R Development Core Team 2007). All hybridizations passed quality control. The data were background corrected and normalized with the probe level quantile method. The probes with intensity level lower than the 95 percentile of negative controls of the BeadChip in all samples were disregarded before Grade  pT  pN  Stage  S12C, S12T  F  42  Tonsillar fossa  G2  T2  N3  IV  S14C, S14T  M  61  Larynx  G2  T3  N0  III  S15C, S15T  M  59  Tongue margin  G2  T3  N2  IV  S18C, S18T  M  66  Soft palate  G2  T1  N0  I  S20C, S20T  M  63  Soft palate  G2  T1  N2  IV  S21C  M  62  Tonsillar fossa  G2  T2  N0  II [26] on intensities that were variance-stabilized by logarithmic transformation. Annotation provided by bioconductor was used (illuminaHumanv3BeadID.db) [27] . Only transcripts with a false discovery rate (FDR) < 0.05 and fold change < 0.5 or > 2 were reported and used in the downstream analysis. To identify significantly perturbed pathways, we performed SPIA [28] analysis on KEGG pathways: genes with FDR < 0.05 were considered to be differentially transcribed. The data were deposited in the ArrayExpress database under accession number E-MTAB-1516.
Results

Comparison of Serum Expression Profiles of HNSCC Patients and Healthy Individuals.
The global gene expression pattern of the blood samples was analysed using principal component analysis (PCA). In this analysis all 16 HNSCC serum specimens were grouped together and were distinct from the normal specimens, showing that the pattern of gene expression was different in cancer patients and healthy individuals (Figures 1(a) and 1(b) ).
1055 gene transcripts were significantly changed ( < 0.05, with at least a twofold change between normal and cancer serum specimens); see Supplementary Tables S1 and  S2 (see Tables S1 and S2 in the Supplementary Material available online at http://dx.doi.org/10.1155/2014/408683/). After correction to FDR (false discovery rate), we obtained 159 gene transcripts that were significantly changed ( value < 0.05). Among these genes, we found the following groups as the most interesting: genes involved in the p53 signalling pathway (p53, p21, cyclinD, MDM2, CASP3, and MAX) and genes of the B-cell lymphoma (Bcl-2) family of proteins (Bcl-2, Bcl-XL, Bcl2L1, Mcl1, and BclAF1).
Deregulated Myc Expression in HNSCC Patients.
We found deregulated Myc expression (MAX: Myc associated factor X, = 0.0099, logFC = 1.77 in the cancer-control group and = 0.0055, logFC = 2 in the treated-control group) and upregulation of proapoptotic transmembrane protein Bim in different isoforms (TMBIM4 (transmembrane BAX inhibitor motif containing 4), = 0.019, logFC = 1.78, and TMBIM1, = 0.024, logFC = 1.69 in the cancer-control group and TMBIM4, = 0.078, logFC = 1.36 and TMBIM1, = 0.038, logFC = 1.61 in the treated-control group). H   S08H  S01H  S07H  S02H  S03H  S04H  S05H  S06H  S33C  S43C  S66C  S15C  S22C  S42C  S14C  S40C  S12C  S24C  S31C  S18C  S29C  S21C  S23C  S20C   EEF1A1  RPL38  LOC654194  RPS27  ANXA2  ANXA2P1  RPL31  RPS17  LOC643949  RPL14  RUNX3  RPL19  LOC653314  LCP1  LYZ  SRRM2  RPS27A  RPL30  C17ORF45  RPL8  CD74  CD74  RPL9  LOC651436  RPLP2  RPL5  RPLP1  RPS17  RPL7  RPL7  LOC441032  LOC648659  LOC146053  EIF3E  LOC653773  RPL18A  RPL18A  RPL18A  RPS10  RPS14  LOC390876  RPS28  GLTSCR2  HNRNPA1P12  LOC645385  LITAF  CLEC2D  TXNIP  LOC387867  LOC652624  LOC648249  LOC388122  LOC389672  HSP90AB1  HS.554324  LOC402057  RPS15  RPLP1  LOC346950  LOC644029  IK  RPL39  EEF1G  EEF1B2  CNOT8  RPS26P11  UTP3  RPL35  LOC440737  MGEA5  EIF4A2  RPS9  RPS9  RBM10  ARHGAP9  LOC389435  LOC650646  BTG1  CCT8P1  CNBP  RPS15A  LOC391656  LOC390354  IFP38  RPL29  RPL29  RPL10  RPL10  NSA2  FCN1   ATP6V1B2  HLA-DRA  EIF3K  CLEC4A  GLIPR2  G3BP1  BST2  ZFP36L2  HNRNPD  GGA3  HSPD1  DNAJC25-GNG10  LST1   LOC644992  LOC650298  PPBP  NFS1  LOC643138  TFPI  TFPI  LOC649260  GUCY1B3  KIF2A  SOD2  MYL9  APP  CTSA  TAGLN2  NRGN 
Differences in Gene Expression in HNSCC Patient
Serum before and 1 Year after Treatment. We compared 12 HNSCC serum samples from the same donors before and 1 year after treatment. The global gene expression analysis showed 246 changed genes ( < 0.05, with at least a twofold change). However, there were no significantly changed genes after FDR correction, demonstrating that the changes were less than those between cancer and normal serum samples.
Signalling Pathway Analysis.
Genes that were differentially expressed ( < 0.05) were analysed using signalling pathway impact analysis (SPIA) of the KEGG pathways. This combines the evidence obtained from the classical enrichment analysis with a novel type of evidence, which measures the actual perturbation on a given pathway under a given condition. In our dataset we were able to identify the pathways that were differentially activated or inhibited (FDR < 0.05) in serum of cancer patients and healthy individuals. The pathways that were significantly activated in our dataset were connected with antigen processing and presentation, focal adhesion, viral carcinogenesis, regulation of actin cytoskeleton, and chemokine signalling pathway or were involved in several viral infections (e.g., herpes simplex, influenza A, human T-lymphotrophic virus-I, and viral myocarditis). By contrast, the significantly inhibited pathways involved RNA transport, leukocyte transendothelial migration, naturalkiller-cell-mediated cytotoxicity, and pathways connected with some neurodegenerative or autoimmune diseases (e.g., Parkinson's disease, Huntington's disease, and rheumatoid arthritis) ( Table 2 ). These findings were further supported by gene set enrichment analysis (GSEA) on the KEGG pathways, which showed significant deregulation of related pathways and downregulation of pathways connected with overall metabolism, RNA transport and degradation, and similar neurodegenerative diseases (Supplementary Table S3 ).
Using GSEA on GO (gene ontology) terms, we found that the following influenced the biological processes: translational processes; ribosomal biogenesis; viral transcription; negative regulation of DNA damage response-signal transduction by p53 class mediator; induction of apoptosis; and several integrin-or interferon-mediated pathways. In terms of cellular compartment we detected changes mainly in the cytosolic or nuclear compartment (Supplementary Tables S4  and S5 ).
Discussion
Carcinogenesis and tumour progression are complex and progressive processes that are associated with numerous genetic and epigenetic alterations that can be detected in plasma or serum. Although there is a long history of investigation of circulating mRNA as a potential biomarker, not many relevant studies have used whole-genome microarray profiling [29, 30] . The aim of many microarray experiments is to determine the global genetic alterations that distinguish cancer cells from their normal counterparts. In our previous studies we mainly focused on the global transcriptome of cancer tissues in comparison with normal epithelium and especially peritumoural tissue. We have shown that paracrine secretion of growth factors, such as insulin-like growth factor-2 (IGF-2) and bone morphogenetic protein-4 (BMP-4), can elucidate the biological activity of stromal fibroblasts to normal keratinocytes by markedly influencing their phenotype. The induced keratinocytes acquire the appearance of squamous cell carcinoma keratinocytes or keratinocytes of wounded skin [31] [32] [33] [34] [35] .
In light of these experiments, we tried to focus on markers that could potentially be present in the serum of cancer patients. There are several theories about how CNAs are released into the bloodstream. CNAs enter the bloodstream after apoptosis of nucleated cells or after tumour necrosis or are actively released into the circulation by tumour cells [36] [37] [38] . We need to realize that the changes in the different transcripts in the serum arise from a heterogeneous cell population-tumour cells, nucleated cells such as lymphocytes or monocytes, as well as a small number of thrombocytes. That is why we can expect changes in genes connected with cell death and tumour suppression, proliferation, and differentiation. There have been several studies using wholegenome microarray profiling to detect differences in serum gene expression in different types of solid tumours [39] [40] [41] [42] as well as haematopoietic malignancies [43] [44] [45] . In our present study we adopted a similar design using whole-genome microarray profiling. What was particularly interesting was the combination of three different groups of samples, from patients before and after treatment as well as from healthy individuals.
As in numerous previous studies, we found that the apoptotic pathway was altered in the patients. Apoptosis is a major barrier to oncogenesis [46, 47] and is triggered by several factors that act through two major pathways: extrinsic and intrinsic pathways [48, 49] . In vertebrates most apoptosis proceeds through the intrinsic pathway. A regulator of this process is the Bcl-2 family of proteins [50] . The family comprises both antiapoptotic or prosurvival members (which can be divided into two subclasses: Bcl-2, Bcl-XL, and Bcl-w and Mcl-1 and A1) and proapoptotic members (the BAX subfamily that includes BAX, BAK, and BOK and the BH3-only subfamily that includes BID, BIM, BAD, BIK, BMF, PUMA, NOXA, and HRK) [51, 52] . The balance between these proteins determines whether a cell commits apoptosis, and the main regulator of these processes is p53. The identification of a myriad of proapoptotic p53 targets that bind and inhibit antiapoptotic Bcl-2 family members suggests that it is only through the combined transcriptional activation of numerous proapoptotic targets that p53 exerts its full apoptotic capability. Similarly, a combination of p53-dependent and -independent signals establishes a total apoptotic burden in a cell that stands in opposition to the prosurvival function of Bcl-2. In our study we revealed significant difference in presence of p53 transcripts in serum of cancer-control group gene expression of p53 in cancercontrol group ( = 0.00031; logFC = −2.24) and in treatedcontrol group ( = 0.019; logFC = −1.79), respectively. In contrast, we did not find a significant difference in expression in the cancer-treated group. As far as Bcl-2 family proteins are Table 2 : SPIA comparison of cancer serum specimens and healthy individuals serum specimens shows significant upregulation of pathways involved in antigen processing and presentation, focal adhesion, viral carcinogenesis, regulation of actin cytoskeleton, and downregulation of pathways involved in RNA transport, leukocyte transendothelial migration, natural-killer-cell-mediated cytotoxicity, and pathways connected with some neurodegenerative or autoimmune diseases. concerned, we detected a significant difference in expression of Bcl-2 and Bcl-XL transcripts in the treated-control group (Bcl-2, = 0.004, logFC = −1.21; Bcl-XL, = 0.006, logFC = 1.67). Overexpression of Bcl-XL in the treated group was evident and was 3.5 times higher than in the control group. In contrast, we did not detect a significant difference in expression of Bcl-2 family proteins in the cancer-control group (Bcl-2, = 0.085; Bcl-XL, = 0.14). In some studies overexpression of the antiapoptotic proteins Bcl-2 and Bcl-XL is associated with chemotherapy and radiation resistance [53, 54] , and the combination of p53 status and Bcl-XL is associated with cisplatin resistance in HNSCC cells in vitro [55, 56] . The combination of low p53 and high Bcl-XL expression is associated with poor overall survival and disease specific survival [55, 57] . The negligible effect of HNSCC treatment on the activity of the above-mentioned genes, based on the level of cRNA, can be interpreted according to our recent results demonstrating differentiation-dependent expression of the endogenous lectin galectin-9 in normal squamous cell epithelium and in cancer [58] . Although normal squamous epithelium from noncancer patients demonstrated strictly basal cell expression, the malignant epithelium of tumours and a significant amount of histologically normal epithelium from HNSCC patients were devoid of expression of this lectin. This indicates some abnormality of histologically normal epithelial layer. These data suggest that the normal epithelium is damaged at the molecular level but to a lesser extent and complexity than is necessary for tumour formation. It harmonizes with hypothesis about field cancerisation [59] .
Included in the apoptotic load are a number of BH3-only proteins that show no obvious regulation by p53 yet antagonise Bcl-2 function in response to specific cellular stresses (Figure 2) . First, the BH3-only proteins Bim, Bad, and Hrk are induced by cytokine deprivation in a p53-independent manner [60] , yet these proteins may synergize with p53-induced pathways to overcome the antiapoptotic threshold set by Bcl-2 and promote cell death. Second, deregulated Myc expression promotes p53-dependent apoptosis [61] , but it also promotes the p53-independent activation of the proapoptotic BH3-only proteins Bim and Bax [62, 63] . Thus, p53-dependent and -independent signals act in parallel to promote cell death and suppress tumourigenesis. The combined strength of these signals is required to overwhelm the antiapoptotic Bcl-2 family members such that inactivation of any one of several prodeath effectors can drop the system below its apoptotic firing threshold and allow unabated proliferation. Myc is an important factor which regulates the expression of cellular targets involved in a wide range of diverse cellular functions, including cell growth, proliferation, loss of cell-cell contact, loss of differentiation, and angiogenesis. In our study we showed deregulated Myc expression in serum of HNSCC patients. Activation of Myc has been shown to cause cell growth, loss of differentiation, and cell cycle entry in suprabasal keratinocytes in vivo [64] .
Our hypothesis is that apoptosis is altered in cancer patients due to resistance of Bcl-XL to p53-independent stimulation by Myc (MAX), potentially Bax, or other BH3-only proteins. The mechanisms of action of Bcl-2 and Bcl-XL are complex, with many postulated interactions with other proteins, and the role of any single interaction in the final phenotype at cellular level remains ill-defined. In some studies Bcl-XL has been ∼10 times more active than Bcl-2 in repressing apoptosis in breast cancer cell lines [65] . When examined in the same cellular context, Bcl-2 and Bcl-XL differ substantially in the potency with which they inhibit apoptosis, mediated in part by differences in the inhibition of specific subcellular pathways.
Concerning the global difference in presence of transcripts in same patients before and one year after treatment, the principal component analysis (PCA) showed positive shift in treated patients in higher presence of transcripts corresponding more with the population of healthy individuals (see Figure 1(a) ). This time period was not sufficient to make definite conclusions because some residual disease was present or patients underwent radical oncological treatment and the organism is not balanced yet. Nevertheless, there was a positive shift in PCA, which demonstrated that this method could be beneficial in the control of tumour recurrence.
The convergence of p53 on various aspects of Bcl-2 biology highlights the crucial role of this interaction in tumour suppression and drug response. Thus, promoting the p53-Bcl-2 interaction seemingly provides an ideal strategy for anticancer therapy. The relevance of specific p53-induced effector proteins and antiapoptotic Bcl-2 family members may vary in distinct tumourigenic contexts; therefore, understanding the precise apoptotic pathways abrogated in specific malignancies will be essential for devising targeted proapoptotic therapy. This includes expanding our understanding of how parallel apoptotic pathways synergise with p53-Bcl-2 signalling to promote cell death. We assumed that in cells the essential difference between Bcl-2 and Bcl-XL involved regulation of expression, probably due to expression in different tissues or in the same tissue but at different times.
We suggest that microchip analysis of serum cRNA in patients with HNSCC should be suitable for refinement of early stage diagnosis of disease that could be important for development of new personalised strategies in diagnosis and treatment of tumours. Either analysis of serum specimens of patients one year after treatment shows promising results in the meaning of shift to the population of healthy individuals.
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